Saavedra, Pedro H. V. http://orcid.org/0000-0002-7659-4533
Trzeciak, Alissa J. http://orcid.org/0000-0002-4518-0098
Lipshutz, Allie http://orcid.org/0000-0002-1786-7300
Daman, Andrew W. http://orcid.org/0000-0001-8144-0574
O’Neal, Anya J. http://orcid.org/0000-0001-5188-1344
Liu, Zong-Lin
Wang, Zhaoquan http://orcid.org/0000-0001-8227-0941
Romero-Pichardo, Jesús E. http://orcid.org/0000-0002-4400-5765
Rojas, Waleska Saitz
Zago, Giulia
van den Brink, Marcel R. M. http://orcid.org/0000-0003-0696-4401
Josefowicz, Steven Z.
Lucas, Christopher D. http://orcid.org/0000-0002-7523-0295
Anderson, Christopher J. http://orcid.org/0000-0003-2600-0968
Rudensky, Alexander Y. http://orcid.org/0000-0003-1280-2898
Perry, Justin S. A. http://orcid.org/0000-0003-4063-6524
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R00CA237728, P30CA008748)
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (1DP2GM146337)
Wellcome Trust (225923/Z/22/Z)
RCUK | Medical Research Council (MR/X019314/1, MR/W019264/1)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI148416)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (RM1GM139738)
Burroughs Wellcome Fund (PATH)
Article History
Received: 8 May 2024
Accepted: 11 July 2024
First Online: 9 August 2024
Competing interests
: J.S.A.P. is a cofounder of Atish Technologies. A.Y.R. is a Scientific Advisory Board member and has equity in Sonoma Biotherapeutics, Santa Ana Bio, RAPT Therapeutics and Vedanta Biosciences. He is a Scientific Executive Board member of Amgen and BioInvent and is a co-inventor or has intellectual property (IP) licensed to Takeda that is unrelated to the content of the present study. M.R.M.v.d.B. has received research support and stock options from Seres Therapeutics, and stock options from Notch Therapeutics and Pluto Therapeutics; he has received royalties from Wolters Kluwer; he has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, Vor Biopharma, Rheos Medicines, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Ceramedix, Lygenesis, Pluto Therapeutics, GlaksoSmithKline, Da Volterra, Thymofox, Garuda, Novartis (Spouse), Synthekine (Spouse), Beigene (Spouse) and Kite (Spouse); he has IP Licensing with Seres Therapeutics and Juno Therapeutics; and he holds a fiduciary role on the Foundation Board of DKMS (a nonprofit organization). Memorial Sloan Kettering has institutional financial interests relative to Seres Therapeutics. The other authors declare no competing interests.